|
MechanismSARS-CoV-2 antigen inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.IN |
First Approval Date03 Jan 2021 |
100 Clinical Results associated with Vaccigen Ltd.
0 Patents (Medical) associated with Vaccigen Ltd.
100 Deals associated with Vaccigen Ltd.
100 Translational Medicine associated with Vaccigen Ltd.